Measurements of Proton, Helium and Muon Spectra at Small Atmospheric Depths with the BESS Spectrometer

The cosmic-ray proton, helium, and muon spectra at small atmospheric depths of 4.5 -- 28 g/cm^2 were precisely measured during the slow descending period of the BESS-2001 balloon flight. The variation of atmospheric secondary particle fluxes as a function of atmospheric depth provides fundamental information to study hadronic interactions of the primary cosmic rays with the atmosphere.Comment: 21 pages, 11 figures, 4 table

Precise Measurements of Atmospheric Muon Fluxes with the BESS Spectrometer

The vertical absolute fluxes of atmospheric muons and muon charge ratio have been measured precisely at different geomagnetic locations by using the BESS spectrometer. The observations had been performed at sea level (30 m above sea level) in Tsukuba, Japan, and at 360 m above sea level in Lynn Lake, Canada. The vertical cutoff rigidities in Tsukuba (36.2 N, 140.1 E) and in Lynn Lake (56.5 N, 101.0 W) are 11.4 GV and 0.4 GV, respectively. We have obtained vertical fluxes of positive and negative muons in a momentum range from 0.6 to 20 GeV/c with systematic errors less than 3 % in both measurements. By comparing the data collected at two different geomagnetic latitudes, we have seen an effect of cutoff rigidity. The dependence on the atmospheric pressure and temperature, and the solar modulation effect have been also clearly observed. We also clearly observed the decrease of charge ratio of muons at low momentum side with at higher cutoff rigidity region.Comment: 35 pages, 9 figures. Submitted to Astroparticle Physic

Precision Measurement of Cosmic-Ray Antiproton Spectrum

The energy spectrum of cosmic-ray antiprotons has been measured in the range 0.18 to 3.56 GeV, based on 458 antiprotons collected by BESS in recent solar-minimum period. We have detected for the first time a distinctive peak at 2 GeV of antiprotons originating from cosmic-ray interactions with the interstellar gas. The peak spectrum is reproduced by theoretical calculations, implying that the propagation models are basically correct and that different cosmic-ray species undergo a universal propagation. Future BESS flights toward the solar maximum will help us to study the solar modulation and the propagation in detail and to search for primary antiproton components.Comment: REVTeX, 4 pages including 4 eps figure

A Precise Measurement of Cosmic-Ray Proton Spectrum with BESS Spectrometer

Abstract We report on the absolute cosmic-ray proton spectrum in the energy range 1 to 120 GeV as measured by the '98 balloon flight of the BESS spectrometer, which was launched from Lynn Lake, Manitoba, Canada. The rigidity of the cosmic-ray was measured reliably by continuous tracking in a uniform magnetic field of 1 Tesla. Background-free particle identifications were achieved by the combination of redundant Ü and TOF measurements. The interaction loss was corrected by using Monte Carlo simulations. Atmospheric secondary protons were subtracted by adopting the calculation of Papini et al.

Successive Measurements of Cosmic-Ray Antiproton Spectrum in a Positive Phase of the Solar Cycle

The energy spectrum of cosmic-ray antiprotons has been measured by BESS successively in 1993, 1995, 1997 and 1998. In total, 848 antiprotons were clearly identified in energy range 0.18 to 4.20 GeV. From these successive measurements of the antiproton spectrum at various solar activity, we discuss about the effect of the solar modulation and the origin of cosmic-ray antiprotons. Measured antiproton ratios were nearly identical during this period, and were consistent with a prediction taking the charge dependent solar modulation into account.Comment: 15 pages, 5 figure

Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan - Insights From GARFIELD-AF -

Background: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective non-interventional study of stroke prevention in patients with newly diagnosed non-valvular AF (NAVF) that is being conducted in 35 countries

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events